❓️Can we avoid ReTURBT in selected patients with T1 NMIBC? ✅️ According to our study YES! 👥️A response-based approach can spare up to 71% of ReTURBT reducing overtreatment Full paper➡️euoncology.europeanurology.c… @EurUrolOncol @urotoday @Uroweb @oncodaily @IBCG_BladderCA

Congratulations to @LauraBukavinaMD @jaymsiva @drjkaouk and @ClevelandClinic team on largest external validation of the IBCG IR NMIBC substratification model 📊 2822 patients | 20 years | 3-year recurrence by subgroup: 🟢 IR-low: 12% 🟡 IR-intermediate: 38% 🔴 IR-high: 77% Progression followed the same stepwise pattern. Fine-Gray competing-risk models confirmed significance (p<0.001) - separation held on 12-month landmark analysis, ruling out early-event bias. Yet more evidence that trials enrolling IR NMIBC should stratify by IBCG subgroup at enrollment to be clinically meaningful. Conflating patients with 12% and 77% recurrence risk in the same trial arm is a fundamental problem. Full text: authors.elsevier.com/sd/arti… @IBCG_BladderCA

A multi-center study examines maintenance schedules for intermediate-risk #NMIBC. @RobertoContieri @IstTumori joins @UroDocAsh @UTMDAnderson to discuss the results which include two-year recurrence-free survival of 55% with no maintenance versus 78% with any maintenance. Classification and regression tree analysis identified optimal cutoff at more than six monthly instillations. #WatchNow on UroToday > bit.ly/3OEHP5m

1) Approval based on marginal improvements in efficacy (without improvement to CSS/OS) 2) Toxicity that isn't G5 (death) doesn't seem to impact approval. 10-15% serious autoimmune AEs in NMIBC is deemed ok 3) little weight given to efficacy vs toxicity balance of a drug

Excellent lecture by @SScagliarini_ on the growing importance of patient-reported outcomes in oligometastatic RCC. A crucial reminder that beyond oncologic endpoints, understanding the patient perspective is essential to truly optimize treatment strategies. @Synergy_Uro @Uroweb

Great pleasure having Prof. Axel Bex at @Synergy_Uro discussing the evolving landscape of locally advanced RCC. Excellent insights and stimulating discussion on current challenges and future directions in kidney cancer care. @eau_yuo @EAUYAU_RenalCa @UrowebESU @EAU_Uroonco

The definitive #SYNERGY26 programme is out 📆 28–29 May | 📍 Naples Locally-advanced & Oigometastatic GU cancers Edition. Program: bit.ly/4w05Zbf

As every year, a packed room for the AUA-IBCG Forum, taking place right now in Salon H. Great discussions and energy around the future of bladder cancer care and research. #AUA2026 #BladderCancer @IBCG_BladderCA @UroDocAsh

Synergy 2026: A Global Exchange on Prostate, Kidney, and Bladder Cancer - Roberto Contieri (@RobertoContieri) oncodaily.com/voices/roberto… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX

SYNERGY 2026 🗓️ 28-29 May 2026 📍 Naples, Italy Preliminary Program: bit.ly/4w05Zbf ✉️ Information & participation: marketing@congredi.it - pandolfosavio@gmail.com

To escalate or de-escalate treatment in BCG-naive HR NMIBC? Our thoughts on the recent JCOG1019 trial by Kitamura et al @EUplatinum Free access to full text 👇🏽 sciencedirect.com/science/ar… @RobertoContieri @LAUrology_NL @UroDocAsh

A multi-center study examines maintenance schedules for intermediate-risk #NMIBC. @RobertoContieri @IstTumori joins @UroDocAsh @UTMDAnderson to discuss the results which include two-year recurrence-free survival of 55% with no maintenance versus 78% with any maintenance. Classification and regression tree analysis identified optimal cutoff at more than six monthly instillations. #WatchNow on UroToday > bit.ly/3OEHP5m

Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial by Roberto Contieri et al Read the full article: buff.ly/AcADjoA We thank the authors for trusting EUO to publish your work @robertocontieri @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @UroDocAsh @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

The International Bladder Cancer Group Travel Award to support outstanding fellows and early-career academic faculty committed to advancing the field of bladder cancer is now offered annually to provide emerging leaders the opportunity to participate in the IBCG Annual Retreat. Details at link: ibcg.info/ibcg-2025-travel-a… #BladderCancer #IBCG26

Pleased to share that the 2026 @NCCN Bladder Cancer Guidelines now incorporate the @IBCG_BladderCa risk stratification framework for intermediate-risk NMIBC. A milestone reflecting more than a decade of collaborative work by colleagues worldwide einpresswire.com/article/901… @UrogerliMD @drtanws @shilpaonc @pjhensley11 @mouwlab @AndreaNecchi @LAUrology_NL @AmirHorowitz @karima_oualla @PGrivasMDPhD @paolo_gontero @pcvblack @MaxKates @SpiessPhilippe @RobertoContieri @KKBree @LauraBukavinaMD @MRoupret @joanfundi @UroToday @BladderCancerUS @WorldBladderCan

We validated BCG failure classifications ~5-year progression ≈30% in both BCG-exposed and BCG-unresponsive groups—but salvage RC is used more often in BCG-unresponsive pts doi.org/10.1111/bju.70231 @Pietro9609 @UroMoschini @BenjaminPradere @RobertoContieri @SBoorjian @BJUIjournal

Roberto Contieri Shares Key Insights on Bladder Cancer Care at EAU 2026 @RobertoContieri oncodaily.com/voices/roberto… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

@tonivilaseca presenting promising early data for intravesical erdafitinib (Erda-iDRS) “TAR 210” in NMIBC presented at #EAU26 ➡️ 83% 12-mo RFS as adjuvant therapy in HR NMIBC (n=26) ➡️ 89% CR at 6 months in IR NMIBC ablative cohort Targeted #FGFR therapy moving earlier into NMIBC disease states. @JoshMeeks @DrFelixGuerrero @IBCG_BladderCA @BladderCancerUS

Which #NMIBC patients may safely receive de-intensified treatment? At #EAU26 @RobertoContieri (@istitutotumori) discusses risk stratification for de-escalation, findings from the ROBUUST database on histological subtypes, and optimizing mitomycin C maintenance in intermediate-risk Ta disease @Uroweb #GUsm #BladderCancer

State-of-the-art lecture treatment de-intensification in #NMIBC. Presentation by @RobertoContieri @IstTumori. #EAU26 written coverage by @chavarriagaj @PSH_Urology > bit.ly/4sgk02k @Uroweb

#EAU26 @RobertoContieri “Less is more” in select NMIBC 🔹 Office-based fulguration 🔹 Active surveillance 🔹 Chemoablation 🎯 The key is patient selection. @uroweb @UroToday